Seong Yong Lim

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/1484430/publications.pdf

Version: 2024-02-01

516710 454955 43 941 16 30 citations g-index h-index papers 43 43 43 1531 docs citations times ranked citing authors all docs

#	Article	IF	Citations
1	Comparison of World Health Organization and Asia-Pacific body mass index classifications in COPD patients. International Journal of COPD, 2017, Volume 12, 2465-2475.	2.3	267
2	Responses to inhaled long-acting beta-agonist and corticosteroid according to COPD subtype. Respiratory Medicine, 2010, 104, 542-549.	2.9	89
3	Lung function decline rates according to GOLD group in patients with chronic obstructive pulmonary disease. International Journal of COPD, 2015, 10, 1819.	2.3	48
4	Metabolic Syndrome, Insulin Resistance and Systemic Inflammation as Risk Factors for Reduced Lung Function in Korean Nonsmoking Males. Journal of Korean Medical Science, 2010, 25, 1480.	2.5	44
5	Validity of the COPD Assessment Test Translated Into Local Languages for Asian Patients. Chest, 2013, 143, 703-710.	0.8	38
6	The Prognostic Value of Residual Volume/Total Lung Capacity in Patients with Chronic Obstructive Pulmonary Disease. Journal of Korean Medical Science, 2015, 30, 1459.	2.5	37
7	Usefulness of open lung biopsy in mechanically ventilated patients with undiagnosed diffuse pulmonary infiltrates: influence of comorbidities and organ dysfunction. Critical Care, 2007, 11, R93.	5.8	35
8	Combination therapy of inhaled steroids and long-acting beta2-agonists in asthma–COPD overlap syndrome. International Journal of COPD, 2016, Volume 11, 2797-2803.	2.3	34
9	Revised (2018) COPD Clinical Practice Guideline of the Korean Academy of Tuberculosis and Respiratory Disease: A Summary. Tuberculosis and Respiratory Diseases, 2018, 81, 261.	1.8	32
10	Association of Plasma Adipokines with Chronic Obstructive Pulmonary Disease Severity and Progression. Annals of the American Thoracic Society, 2015, 12, 1005-1012.	3.2	29
11	Direct and Indirect Costs of Chronic Obstructive Pulmonary Disease in Korea. Tuberculosis and Respiratory Diseases, 2019, 82, 27.	1.8	28
12	Inhaled indacaterol for the treatment of COPD patients with destroyed lung by tuberculosis and moderate-to-severe airflow limitation: results from the randomized INFINITY study. International Journal of COPD, 2017, Volume 12, 1589-1596.	2.3	24
13	<p>Metabolic Syndrome in Early Chronic Obstructive Pulmonary Disease: Gender Differences and Impact on Exacerbation and Medical Costs</p> . International Journal of COPD, 2019, Volume 14, 2873-2883.	2.3	24
14	Association of blood eosinophils and plasma periostin with FEV1 response after 3-month inhaled corticosteroid and long-acting beta2-agonist treatment in stable COPD patients. International Journal of COPD, 2016, 11, 23.	2.3	23
15	Favorable longitudinal change of lung function in patients with asthma-COPD overlap from a COPD cohort. Respiratory Research, 2018, 19, 36.	3.6	23
16	Blood eosinophil count as a prognostic biomarker in COPD. International Journal of COPD, 2018, Volume 13, 3589-3596.	2.3	23
17	Validation of Previous Spirometric Reference Equations and New Equations. Journal of Korean Medical Science, 2019, 34, e304.	2.5	15
18	Mixed Phenotype of Emphysema and Airway Wall Thickening Is Associated with Frequent Exacerbation in Chronic Obstructive Pulmonary Disease Patients. International Journal of COPD, 2019, Volume 14, 3035-3042.	2.3	12

#	Article	IF	CITATIONS
19	Validation of the Lower Limit of Normal Diffusing Capacity for Detecting Emphysema. Respiration, 2011, 81, 287-293.	2.6	11
20	Acute Exacerbation According to GOLD 2017 Categories in Patients with Chronic Obstructive Pulmonary Disease. Archivos De Bronconeumologia, 2019, 55, 414-420.	0.8	11
21	Urinary desmosine is associated with emphysema severity and frequent exacerbation in patients with <scp>COPD</scp> . Respirology, 2018, 23, 176-181.	2.3	10
22	Comparison of Clinical Efficacy and Safety between Indacaterol and Tiotropium in COPD: Meta-Analysis of Randomized Controlled Trials. PLoS ONE, 2015, 10, e0119948.	2.5	9
23	Influence of Environmental Exposures on Patients with Chronic Obstructive Pulmonary Disease in Korea. Tuberculosis and Respiratory Diseases, 2014, 76, 226.	1.8	7
24	Which bronchodilator reversibility criteria can predict severe acute exacerbation in chronic obstructive pulmonary disease patients?. Respiratory Research, 2017, 18, 107.	3.6	7
25	Anemia as a clinical marker of stable chronic obstructive pulmonary disease in the Korean obstructive lung disease cohort. Journal of Thoracic Disease, 2017, 9, 5008-5016.	1.4	7
26	The health-related quality-of-life of chronic obstructive pulmonary disease patients and disease-related indirect burdens. Korean Journal of Internal Medicine, 2020, 35, 1136-1144.	1.7	7
27	Severe vitamin D deficiency is associated with emphysema progression in male patients with COPD. Respiratory Medicine, 2020, 163, 105890.	2.9	6
28	Predicting long-term mortality with two different criteria of exercise-induced desaturation in COPD. Respiratory Medicine, 2021, 182, 106393.	2.9	6
29	Implications of Emphysema and Lung Function for the Development of Pneumonia in Patients with Chronic Obstructive Pulmonary Disease. Tuberculosis and Respiratory Diseases, 2016, 79, 91.	1.8	5
30	The Economic Effect of Early Management in Patients with Early Chronic Obstructive Pulmonary Disease: Results from a Population-Based Nationwide Survey. Lung, 2019, 197, 303-313.	3.3	5
31	Efficacy and safety of ifosfamide in combination with carboplatin and etoposide in small cell lung cancer. Cancer Chemotherapy and Pharmacology, 2015, 76, 933-937.	2.3	3
32	The relationship between serum fatty-acid binding protein 4 level and lung function in Korean subjects with normal ventilatory function. BMC Pulmonary Medicine, 2016, 16, 34.	2.0	3
33	<p>Risk of chronic obstructive pulmonary disease in healthy individuals with high C-reactive protein levels by smoking status: a population-based cohort study in Korea</p> . International Journal of COPD, 2019, Volume 14, 2037-2046.	2.3	3
34	Direct Switch from Tiotropium to Indacaterol/Glycopyrronium in Chronic Obstructive Pulmonary Disease Patients in Korea. Tuberculosis and Respiratory Diseases, 2021, 84, 96-104.	1.8	3
35	Current Situation of Home Oxygen Therapy for Chronic Obstructive Pulmonary Disease Patients in Korea. Journal of Korean Medical Science, 2020, 35, e12.	2.5	3
36	Three-month Treatment Response and Exacerbation in Chronic Obstructive Pulmonary Disease. Journal of Korean Medical Science, 2015, 30, 54.	2.5	2

#	Article	IF	CITATIONS
37	Which GOLD B patients progress to GOLD D with the new classification?. International Journal of COPD, 2018, Volume 13, 3233-3241.	2.3	2
38	Development of Prediction Equation of Diffusing Capacity of Lung for Koreans. Tuberculosis and Respiratory Diseases, 2018, 81, 42.	1.8	2
39	Korean physician prescription patterns for home oxygen therapy in chronic obstructive pulmonary disease patients. Korean Journal of Internal Medicine, 2022, 37, 119-126.	1.7	2
40	Accuracy of Spirometry at Predicting Restrictive Pulmonary Impairment. Tuberculosis and Respiratory Diseases, 2003, 54, 330.	0.2	1
41	Hyperuricemia Is Not Predictive of Long-Term Outcome in Patients with Stable Chronic Obstructive Pulmonary Disease. Journal of Korean Medical Science, 2020, 35, e58.	2.5	1
42	Treatment and prevention of acute exacerbation of chronic obstructive pulmonary disease. Journal of the Korean Medical Association, 2018, 61, 552.	0.3	0
43	Korean Clinical Imaging Guidelines for the Appropriate Use of Chest MRI. Journal of the Korean Society of Radiology, 2021, 82, 562.	0.2	0